Roche’s influenza drug Xofluza gets EU approval
pharmafile | January 11, 2021 | News story | Sales and Marketing | EC, Roche, influenza
The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above.
Xofluza has also received EC approval for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus.
Influenza is one of the most common yet serious infectious diseases, representing a significant threat to public health. Globally, seasonal influenza epidemics result in three to five million cases of severe disease, millions of hospitalisations, and up to 650,000 deaths every year. The WHO estimates that up to 72,000 people in the Europe region die prematurely due to causes associated with influenza each year.
The Commission’s decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in November, and is based on the results of the phase III CAPSTONE-1, CAPSTONE-2, and BLOCKSTONE studies. It marks the first innovation in mechanism of action for an influenza antiviral approved by the EC in almost two decades.
Dr Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said: “We are delighted that the European Commission has approved Xofluza, a first-in-class, single-dose oral medicine, for the treatment of influenza.
“Xofluza offers patients the first novel mechanism of action for treating influenza approved in Europe in almost 20 years. With approval for both treatment and post-exposure prophylaxis, we are hopeful Xofluza will help patients recover more quickly while also reducing the societal burden of influenza, especially amid the COVID-19 pandemic.”
Darcy Jimenez
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
